JCB, Volume 21, Number 3, 2015 Commentary Vol.21 No. 3 (2015) Combating a Global Pandemic of Weak, Adulterated, and Fake Drugs Menghis Bairu Whether it’s willful counterfeiting, sloppy manufacturing processes, or neglectful handing of drugs in the global supply chain, recent studies suggest the problem of weakened, adulter Commentary Vol.21 No. 3 (2015) The Globetrotting Regulator Peter J. Pitts I am putting in a lot of miles on behalf of international regulatory fraternity.Like Johnny Cash said, “I’ve been everywhere†— or at least it seems that Commentary Vol.21 No. 3 (2015) FDA: Is Off-Label on the Table? Peter Pitts Biopharmaceutical companies have the most complete and up-to-date information about the medicines that they research, develop and manufacture for use by patients. However, companies a Commentary Vol.21 No. 3 (2015) A ‘Genetically Engineered’ Label: Way More Expensive Than You Think Henry I Miller Pseudo-controversy continues to rage over whether foods from plants and animals genetically engineered with the newest molecular techniques should have to be labeled as such. The battles, fo Article Vol.21 No. 3 (2015) Cannabis-Derived Pharmaceuticals Clifford S Mintz Cannabis, commonly known as marijuana, weed or pot, is a natural product derived from the Cannabis sativa plant. It has been used medicinally for thousands of years. Rec Article Vol.21 No. 3 (2015) Venture Capitalists as gatekeepers for Biotechnological Innovation Kenneth Fernald Venture capitalists (VCs) aim at trade sales as a preferred exit-strategy for biotechnology companies they invest in. Therefore, VCs pay close attention to the wishes of larger (b From the Boardroom Vol.21 No. 3 (2015) BioTime’s bid to end age-related disease: A look at CEO Michael West’s Vision Ian C. Clift The regenerative medicine space is one that is set to explode with considerable innovation and profitability for shrewd biotechnologists. I had the opportunity to speak with Michael West, Legal and Regulatory Updates Vol.21 No. 3 (2015) EU Legal & Regulatory Update – May 2015 Henry Elliott Conference Report Vol.21 No. 3 (2015) Innovation Landscape, Deal-making Strategies and Success Stories Vasu Pestonjamasp